Search clinical trials for: irAE

Total 16 results

Lawson Health Research Institute

Recruiting

Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer (Pre-PLaN)

Non-small Cell Lung Cancer Stage IB (Resectable) | Non-small Cell Lung Cancer Stage II (Resectable) | Non-small Cell Lung Cancer Stage ⅢA (Resectable)

Canada
Portsmouth Hospitals NHS Trust

Recruiting

BIO-CHECKPOINT 0 Biomarkers to Identify Oncology Patients on ICPI at Greater Risk of irAE

Neoplasms

United Kingdom
Jun Wang

Recruiting

Thymosin Alpha-1 for irAE Secondary to ICIs

IrAE

China
Centre Hospitalier Universitaire, Amiens
Central Hospital Saint Quentin

Recruiting

Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment (Ibe2i-TIPCI)

Immunotherapy | Immune Checkpoint Inhibitors | Immune-related Adverse Event | Predictive Biomarkers

France
Hospices Civils de Lyon

Recruiting

QUALITOP - Monitoring Multidimensional Aspects of QUAlity of Life After Cancer ImmunoTherapy, an Open Smart Digital Platform for Personalized Prevention and Patient Management

Solid Tumor | Hematologic Cancer

Netherlands, France, Portugal, Spain
Diakonhjemmet Hospital
Oslo University Hospital; University Hospital of North Norway; Helse Nord-Trøndelag... and other collaborators

Recruiting

Rheumatic IMmune-Related Adverse Events in Patients Treated With Immune Check Point Inhibitors (RIMRA)

Immune-related Adverse Event

Norway
Manuela Eicher

Recruiting

ePRO-based Model of Care to Manage and Monitoring Symptoms of Cancer Patients Treated With Immune Checkpoint Inhibitors (IePRO)

Patient Reported Outcome Measures | Patient Safety

Switzerland
Jules Bordet Institute

Recruiting

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Melanoma | Renal Cell Carcinoma | Breast Cancer | Head and Neck Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Non Small Cell Lung Cancer | Mesothelioma, Malignant | Bladder Cancer | Gastrointestinal Cancer | Merkel Cell Carcinoma | Non-melanoma Skin Cancer | MSI-H Colorectal Cancer

Belgium
Peking Union Medical College Hospital

Recruiting

irAE Prediction of Anti-PD-1/L1 in Lung Cancer

Lung Cancer | Immune Checkpoint Inhibitors

China
Sir Mortimer B. Davis - Jewish General Hospital

Recruiting

Montreal Immune-Related Adverse Events (MIRAE) Study (MIRAE)

Autoimmune Diseases | Cancer | Immune System Disorder | Inflammatory Reaction

Canada
Columbia University
Genentech, Inc.

Recruiting

Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)

Advanced Solid Tumor | Immune-related Adverse Events

United States
Hospices Civils de Lyon

Recruiting

A Clinical and Biological Prospective Database of Patients Treated With Anticancer Immunotherapy and Follow up of Their Immune-related Adverse Events irAE (IMMUCARE-BASE)

Cancer

France
University of Southern Denmark
Odense University Hospital; University of Copenhagen; Region of Southern Denmark and other collaborators

Active, not recruiting

LIFE - Lung Cancer, Immunotherapy, Frailty, Effect

Quality of Life | Venous Thromboembolism | Non-small Cell Lung Cancer | Brain Metastases

Denmark
Nanjing Medical University

Completed

Immune Checkpoint Inhibitors(ICPis)-Induced Endocrine Immune-related Adverse Events (irAEs)

Immune Checkpoint Inhibitor | Endocrine Toxicity

China
OncoImmune, Inc.
National Cancer Institute (NCI); Huntsman Cancer Institute

Withdrawn

CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) (CINDI)

Metastatic Melanoma

United States
Chang Gung Memorial Hospital

Unknown

WGA in Platinum-refractory HNSCC Underwent Nivolumab

HNSCC

Taiwan

Search clinical trials for: irAE

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations